Evidence map›Paper›PMID 20458558›Full record

ArticleMedical oncology (Northwood, London, England)2011

Significance of estrogen receptor 1 (ESR-1) gene imbalances in colon and hepatocellular carcinomas based on tissue microarrays analysis.

Evangelos Tsiambas, Stavros N Georgiannos, Nikolaos Salemis, Despoina Alexopoulou, Sofia Lambropoulou, Blerta Dimo, Ioannis Ioannidis, Christos Kravvaritis, Andreas Karameris, Efstratios Patsouris and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 26 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Journal of cancer metastasis and treatment · 2019
    Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Evangelos TsiambasDepartment of Pathology, Medical School, University of Athens, and Department of Breast Cancer Surgery, Blue Cross Hospital, str Patriarchou Grigoriou E 17 Ag Paraskevi Attiki, 15341, Athens, Greece. tsiambasecyto@yahoo.gr
Stavros N Georgiannos
Nikolaos Salemis
Despoina Alexopoulou
Sofia Lambropoulou
Blerta Dimo
Ioannis Ioannidis
Christos Kravvaritis
Andreas Karameris
Efstratios Patsouris
Spyridon Dourakis
Evangelismos Hospital · GRNational and Kapodistrian University of Athens · GRHellenic Red Cross · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Estrogen receptor alpha-encoded by ESR1 gene-overexpression correlates with prognosis and response to specific chemotherapy in breast adenocarcinoma cases. Mechanisms of ESR-1 deregulation in carcinomas remain under investigation. To analyze ESR1 in carcinomas of different histogenesis. Using tissue microarray technology, 172 primary carcinomas including breast ductal adenocarcinomas (n=60), hepatocellular carcinomas (n=52), and colon adenocarcinomas (n=60) were cored and re-embedded in three paraffin blocks. Initial diagnosis was based on liquid based cytology (LiquiPrep/ThinPrep). Immunohistochemistry and fluorescence in situ hybridization were performed. Quantitative evaluation of ER-a protein levels was assessed by applying digital image analysis. ER-a overexpression was observed in 41/60 (68.3%), 23/52 (44.2%) and 4/60 (6.6%) cases, respectively. ESR1 gene multiple copies were confirmed in 13/60 (21.6%) breast adenocarcinomas, but high amplification only in 8/13 (62.8%). Allelic absence was identified in 3/52 (5.7%) hepatocellular carcinomas, whereas colon adenocarcinomas demonstrated gene gains in 5/60 (8.3%) cases referred to chr 6 aneuploidy and not to amplification. ER-a overall expression was associated strongly to ESR1 gene copies only in breast carcinoma (P=0.036). ESR-1 gene overexpression happens frequently in breast cancer, but only a subset of them are high amplified cases correlated to increased response rates in hormonal therapy (tamoxifen). Absence of this mechanism in hepatocellular and colon carcinomas maybe is a negative factor for applying this therapy. This is a pattern of histo-genetic depended targeted therapeutic strategy.

Indexed as

AdenocarcinomaBreast NeoplasmsCarcinoma, HepatocellularColonic NeoplasmsEstrogen Receptor alphaFemaleGene AmplificationGene Expression ProfilingHumansImage Interpretation, Computer-AssistedImmunohistochemistryIn Situ Hybridization, FluorescenceLiver NeoplasmsNeoplasm GradingNeoplasm StagingTissue Array AnalysisESR1 protein, humanEstrogen Receptor alpha

Identifiers

PMID20458558
OpenAlexW2068777980

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.